![Jorge Alemany](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jorge Alemany
Directeur des opérations chez Cellerix SA
Postes actifs de Jorge Alemany
Sociétés | Poste | Début | Fin |
---|---|---|---|
Cellerix SA
![]() Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Directeur des opérations | - | - |
Historique de carrière de Jorge Alemany
Anciens postes connus de Jorge Alemany
Sociétés | Poste | Début | Fin |
---|---|---|---|
Onechain Immunotherapeutics
![]() Onechain Immunotherapeutics Medical SpecialtiesHealth Technology Onechain Immunotherapeutics develops oncological therapeutic tools. The company is based in Barcelona, Spain. The Spanish company was founded in 2020 by Pablo Menéndez. The CEO is Jorge Alemany. | Directeur/Membre du Conseil | 11/09/2020 | 01/02/2024 |
Directeur Général | 01/07/2020 | 01/02/2024 | |
Pharmagene Plc | Corporate Officer/Principal | - | - |
Formation de Jorge Alemany
Instituto de Empresa SL | Masters Business Admin |
Statistiques
Internationale
Espagne | 4 |
Royaume-Uni | 2 |
Opérationnelle
Chief Operating Officer | 1 |
Masters Business Admin | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 3 |
---|---|
Cellerix SA
![]() Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Health Technology |
Pharmagene Plc | Health Technology |
Onechain Immunotherapeutics
![]() Onechain Immunotherapeutics Medical SpecialtiesHealth Technology Onechain Immunotherapeutics develops oncological therapeutic tools. The company is based in Barcelona, Spain. The Spanish company was founded in 2020 by Pablo Menéndez. The CEO is Jorge Alemany. | Health Technology |
- Bourse
- Insiders
- Jorge Alemany
- Expérience